Literature DB >> 30525088

With great power comes great vulnerability.

Rodrigo Leite de Oliveira1, Liqin Wang1, Rene Bernards1.   

Abstract

The clinical responses to targeted drugs are often transient and do not always translate into meaningful overall survival due to the development of resistance. We discuss here that the greater power of drug resistant cells can be associated with significant newly-acquired vulnerabilities that can be exploited therapeutically.

Keywords:  BRAF; drug resistance; histone deacetylase inhibitor; melanoma; reactive oxygen species

Year:  2018        PMID： 30525088      PMCID： PMC6276853          DOI： 10.1080/23723556.2018.1509488

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  CROSS RESISTANCE AND COLLATERAL SENSITIVITY STUDIES IN CANCER CHEMOTHERAPY.

Authors:  D J HUTCHISON
Journal:  Adv Cancer Res       Date:  1963       Impact factor: 6.242

2.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

3.  High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.

Authors:  Liqin Wang; Rodrigo Leite de Oliveira; Cun Wang; João M Fernandes Neto; Sara Mainardi; Bastiaan Evers; Cor Lieftink; Ben Morris; Fleur Jochems; Lisa Willemsen; Roderick L Beijersbergen; René Bernards
Journal:  Cell Rep       Date:  2017-10-17       Impact factor: 9.423

4.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Authors:  Chong Sun; Liqin Wang; Sidong Huang; Guus J J E Heynen; Anirudh Prahallad; Caroline Robert; John Haanen; Christian Blank; Jelle Wesseling; Stefan M Willems; Davide Zecchin; Sebastijan Hobor; Prashanth K Bajpe; Cor Lieftink; Christina Mateus; Stephan Vagner; Wipawadee Grernrum; Ingrid Hofland; Andreas Schlicker; Lodewyk F A Wessels; Roderick L Beijersbergen; Alberto Bardelli; Federica Di Nicolantonio; Alexander M M Eggermont; Rene Bernards
Journal:  Nature       Date:  2014-03-26       Impact factor: 49.962

5.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

6.  An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Authors:  Liqin Wang; Rodrigo Leite de Oliveira; Sanne Huijberts; Evert Bosdriesz; Nora Pencheva; Diede Brunen; Astrid Bosma; Ji-Ying Song; John Zevenhoven; G Tjitske Los-de Vries; Hugo Horlings; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens; Rene Bernards
Journal:  Cell       Date:  2018-05-10       Impact factor: 41.582

7.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

Authors:  Muhammed Murtaza; Sarah-Jane Dawson; Dana W Y Tsui; Davina Gale; Tim Forshew; Anna M Piskorz; Christine Parkinson; Suet-Feung Chin; Zoya Kingsbury; Alvin S C Wong; Francesco Marass; Sean Humphray; James Hadfield; David Bentley; Tan Min Chin; James D Brenton; Carlos Caldas; Nitzan Rosenfeld
Journal:  Nature       Date:  2013-04-07       Impact factor: 49.962

8.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Authors:  Meghna Das Thakur; Fernando Salangsang; Allison S Landman; William R Sellers; Nancy K Pryer; Mitchell P Levesque; Reinhard Dummer; Martin McMahon; Darrin D Stuart
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962

9.  Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.

Authors:  Amélie Clémentine Seghers; Sofie Wilgenhof; Céleste Lebbé; Bart Neyns
Journal:  Melanoma Res       Date:  2012-12       Impact factor: 3.599

10.  mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.

Authors:  Clare F Malone; Chloe Emerson; Rachel Ingraham; William Barbosa; Stephanie Guerra; Haejin Yoon; Lin L Liu; Franziska Michor; Marcia Haigis; Kay F Macleod; Ophélia Maertens; Karen Cichowski
Journal:  Cancer Discov       Date:  2017-09-29       Impact factor: 39.397
  10 in total
  2 in total

Review 1.  Understanding and overcoming resistance to PARP inhibitors in cancer therapy.

Authors:  Mariana Paes Dias; Sarah C Moser; Shridar Ganesan; Jos Jonkers
Journal:  Nat Rev Clin Oncol       Date:  2021-07-20       Impact factor: 66.675

Review 2.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Authors:  Alessandro Leonetti; Sugandhi Sharma; Roberta Minari; Paola Perego; Elisa Giovannetti; Marcello Tiseo
Journal:  Br J Cancer       Date:  2019-09-30       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.